What Amoeba does

Amoéba is a French industrial greentech company founded in 2010 and headquartered in Chassieu (Lyon metropolitan area), listed on Euronext Growth Paris (ticker ALMIB, ISIN FR0011051598). The company develops and commercializes biological solutions based on a proprietary non-pathogenic amoeba, Willaertia magna C2c Maky. The amoeba is mechanically lysed to produce a biocontrol active substance with fungicidal properties against oomycetes (downy mildew) and phytopathogenic fungi such as rusts and powdery mildew. Production uses a proprietary 3D suspension culture process with continuous perfusion bioreactors, reducing footprint from 21,500 m² (adhesion culture) to 2 m² for equivalent output. The company holds four granted patent families and an exclusive license from University Claude Bernard Lyon I, and is the only entity authorized to industrially exploit this microorganism for biocontrol and cosmetic applications.

Amoéba's core product is AXPERA (commercially rebranded TIAGAN for viticulture by Koppert), a biofungicide approved as an EU low-risk substance (2025) and by the US EPA (2022), with US market authorization received October 2025 and French ANSES evaluation in final phase as of February 2026. Emergency authorizations have been obtained in France (2025, 2026) and Italy (2026), with exceptional trial permits in the Netherlands (2026). Field trials in French vineyards showed 57.7% downy mildew symptom reduction with AXPERA + reduced copper vs 37.5% with standard copper programs. A secondary product, BIOMEBA, is a biological biocide targeting Legionella pneumophila in industrial cooling and sanitary water systems. Cosmetic ingredients derived from the lysate are listed on INCI for worldwide commercialization (excluding China, where local approval is required).

The company operates a partner-led go-to-market model. An exclusive 5-year distribution agreement with Koppert (June 2025) covers vines and vegetable crops across 18 European countries and the US, with a Memorandum of Understanding with Syngenta (November 2025) targeting cereals and field crops in the EU and UK. Commercial operations are managed through the wholly-owned Green 4 Agro subsidiary, headed since March 2026 by Jean-Marc Petat (formerly of BASF Group). The company is pre-revenue as of FY2025 (net loss of €8.3M, cash position €4.7M, financial debt €12.2M), with first commercial orders from Koppert received March 2026 and deliveries scheduled from April 2026, marking the transition from a regulatory-development stage to commercial-stage entity.

Name

Amoeba

Legal name

AMOEBA (Société anonyme à conseil d'administration au capital de 993 199,26 €)

Website

https://amoeba-nature.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Amoéba is a French greentech company that develops biological crop protection products based on the amoeba Willaertia magna C2c Maky, primarily serving winegrowers and vegetable growers in Europe and the US through exclusive partnerships with Koppert and Syngenta.

Ownership category

akta.pro rank

Product category

Biological crop protection (biocontrol)

NAICS

Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Chemical Manufacturing (325)

SIC

Agricultural Chemicals (2870), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Microbial Biopesticides (Bacterial, Fungal, Viral) (AFABAEAA)

akta.pro secondary industries

Biological Pest Control (Beneficial Insects, Nematodes, Microbials) (AFABAKAB), Industrial Biocides & Preservatives (IMAEABAH)

Keywords

• Biological crop protection
• Biocontrol biofungicides
• Plant disease management
• Biological water treatment
• Amoeba-based biosolutions

Headquarters

HQ city

Chassieu

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biocontrol products (AXPERA/TIAGAN): Sale of biocontrol products for plant protection (biofungicide) based on Willaertia magna C2c Maky lysate. Commercial launch expected in 2026 following marketing authorization. Distributed through Koppert in 18 European countries and US. Revenue not yet generated as of FY2025.
2. Cosmetics ingredients: Cosmetic ingredient (amoeba lysate) listed on INCI (International Nomenclature of Cosmetic Ingredients), enabling commercialization worldwide except in China where local approval is required. No prior regulatory approval required in Europe or US.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Amoéba develops and commercializes biological products based on the amoeba Willaertia magna C2c Maky. Its core offering includes AXPERA/TIAGAN biocontrol biofungicides for crop protection (targeting downy mildew, rusts and powdery mildew in vineyards, vegetables and cereals), BIOMEBA biological biocide for industrial water treatment (Legionella control), and INCI-listed cosmetic ingredients derived from the same amoeba lysate.

Product overview

Amoeba is a French greentech company that has developed a unique technology platform based on the microorganism Willaertia magna C2c Maky. The company offers biological solutions across two main markets: (1) Biocontrol for plant protection, with AXPERA/TIAGAN as biofungicides targeting downy mildew, rust, and fungal diseases in vineyards, vegetables, and cereals; and (2) BIOMEBA as a biological biocide for industrial water treatment against Legionella. The core technology uses mechanically lysed amoeba which demonstrates fungicidal properties. The company operates through its Green 4 Agro subsidiary for agricultural biosolutions and holds exclusive licenses to patents from University Claude Bernard Lyon I for various applications. Commercialization is underway in Europe and the US following regulatory approvals.

Differentiator

Problem solved

Functional benefit

Brands

• AXPERA: Biocontrol biofungicide product based on Willaertia magna C2c Maky lysate for plant protection against fungal diseases.
• TIAGAN
• Green 4 Agro
• BIOMEBA

Products and services

• AXPERA (biocontrol biofungicide) Biocontrol biofungicide based on mechanically lysed Willaertia magna C2c Maky amoeba, providing fungicidal properties against fungal plant diseases including downy mildew, rust, and powdery mildew. Marketed as a biological alternative to chemical pesticides and copper.
• TIAGAN (viticulture brand of AXPERA)

Quantifiable outcome

• 57.7% reduction in downy mildew symptoms with AXPERA + reduced copper dose vs 37.5% with standard copper programme in vineyard field trials (2024)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Syngenta Crop ProtectioncoreChannel Partner/ Reseller/ Distributor · 18 November 2025Memorandum of Understanding signed November 2025 to develop and commercialize bio-fungicides based on amoeba lysate for cereal crops in Europe and UK. Focus on wheat diseases (septoria tritici blotch, yellow rust) causing significant yield losses. Distribution agreement expected to be finalized by spring 2026. Syngenta is a global leader in crop protection.
• KoppertcoreChannel Partner/ Reseller/ Distributor · 1 June 2025Exclusive 5-year distribution agreement signed June 2025 grants Koppert exclusive rights to distribute AXPERA/TIAGAN for vines and vegetable crops in 18 European countries and the United States. Koppert, world leader in biocontrol with ~2,750 employees and operations in over 100 countries, announced the TIAGAN brand for viticultural uses. First order received March 2026 with deliveries from April 2026. Collaboration also extends to Brazil under strategic agreement, testing AXPERA on soybeans and citrus.
• Koppert BrazilminorChannel Partner/ Reseller/ Distributor · 1 June 2025Field trial program conducted in Brazil with Koppert Brazil testing AXPERA on strategic crops (soybeans and oranges). Brazil market valued at nearly €1 billion for bio-inputs. Regulatory approval expected 2027, commercialization targeted 2028.
• IFV+ (Institut Français de la Vigne et du Vin)minorStrategic or Co-development Partner · 25 November 2024Partnership with IFV+ for field trials of AXPERA against downy mildew in French vineyards. IFV+ advocated for emergency authorization supporting large-scale field trials with winegrowers. Trial in Gaillac appellation showed 57.7% symptom reduction with AXPERA + reduced copper vs 37.5% with standard copper.
• Oriental Beauty Valley Group (China)minorStrategic or Co-development PartnerAgreement signed July 2025 with both regulatory and commercial scope in China for cosmetics ingredients. China requires local approval for cosmetic ingredients (INCI listed ingredient can be marketed worldwide except in China).

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• AgBiome: US-based microbial crop protection and discovery company developing biological fungicides, insecticides, and nematicides from microbial libraries. Comparable to Amoéba as an emerging player using a proprietary platform to commercialize novel biological actives.

Direct peers

• Koppert: Royal Koppert is the world's leading biocontrol company (~2,750 employees, 100+ countries) and is Amoéba's exclusive distribution partner for AXPERA/TIAGAN across 18 European countries and the US. It directly competes in microbial and biological crop protection for horticulture, fruits, and field crops.
• Biobest Group: Belgian biological crop protection specialist with a broad biocontrol portfolio spanning beneficial insects, mites, and microbials. Comparable to Amoéba because it competes in the same IPM/biocontrol channel serving horticulture and specialty crop growers in Europe and the Americas.
• Lallemand Plant Care: Division of Lallemand focused on microbial-based plant care products (biocontrol, biostimulants, biofertilizers). Directly comparable to Amoéba in using microbial active substances to suppress fungal diseases and improve plant health in specialty and field crops.
• Bioceres (incl. Marrone Bio Innovations): Latin American agricultural biologicals leader with global reach (acquired Marrone Bio in 2023). Directly comparable to Amoéba in bringing microbial biocontrol to soybean, corn, and horticulture — and especially relevant given Amoéba's Brazil soy/citrus ambitions.
• Certis Biologicals: US-headquartered specialist in biological crop protection with a portfolio of biofungicides, bioinsecticides, and bionematicides. Highly comparable to Amoéba as a focused biocontrol competitor targeting fungal diseases in fruit, vegetable, and row crops.

Broad incumbents

• Bayer Crop Science: Global crop protection and seeds major with biologicals initiatives (e.g., Biologics, AgPowered). Comparable to Amoéba as a broad incumbent expanding into microbial and biocontrol solutions across cereals, vegetables, and specialty crops.
• BASF Agricultural Solutions: One of the world's largest crop protection companies, with a growing biologicals portfolio. Directly relevant because Jean-Marc Petat (now MD of Green 4 Agro, Amoéba's commercial subsidiary) spent nearly 30 years at BASF, and BASF competes head-to-head with AXPERA in vineyard and cereal fungicides.
• Corteva Agriscience: Global agricultural inputs major with both conventional and biological crop protection offerings. Comparable to Amoéba as a broad incumbent that competes in cereal and vegetable fungicides targeted by AXPERA, with growing investment in biocontrol.
• Syngenta Crop Protection: Global leader in crop protection chemicals and seeds with a growing biocontrol portfolio. Partnered with Amoéba via MoU (November 2025) for cereals in EU/UK, directly comparable because it sells competing fungicides (e.g., for septoria and rust) that Amoéba's biofungicide targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCP4OFk376FMp8fzFigAryjA
• LinkedInfr.linkedin.com/company/amoeba-nature
• Xx.com/amoebanature

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amoeba